



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
02.08.2023 Bulletin 2023/31

(45) Date of publication and mention
of the grant of the patent:
07.06.2023 Bulletin 2023/23

(21) Application number: **20200633.4**

(22) Date of filing: **30.04.2008**

(51) International Patent Classification (IPC):
C07D 221/28 ^(2006.01) **C07B 59/00** ^(2006.01)
A61K 31/439 ^(2006.01) **A61P 11/14** ^(2006.01)

(52) Cooperative Patent Classification (CPC):
A61K 31/195; A61K 31/4709; A61K 31/485;
A61K 31/49; A61P 11/00; A61P 11/14;
A61P 25/00; C07B 59/002; C07D 221/28;
C07D 471/08; G01N 33/491; G01N 33/493

(54) **MORPHINAN COMPOUNDS**
MORPHINANVERBINDUNGEN
COMPOSÉS DE MORPHINANE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT
RO SE SI SK TR

(30) Priority: **01.05.2007 US 91513007 P**
08.05.2007 US 91666207 P
28.09.2007 US 97604407 P

(43) Date of publication of application:
26.05.2021 Bulletin 2021/21

(60) Divisional application:
22199041.9 / 4 183 787

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
19201663.2 / 3 632 916
17206213.5 / 3 357 923
16163718.6 / 3 093 290
14173190.1 / 2 792 662
11000764.8 / 2 357 183
08747238.7 / 2 152 709

(73) Proprietor: **Sun Pharmaceutical Industries, Inc.**
Princeton, NJ 08540 (US)

(72) Inventor: **TUNG, Roger**
Lexington, Massachusetts 02420 (US)

(74) Representative: **Marks & Clerk LLP**
15 Fetter Lane
London EC4A 1BW (GB)

(56) References cited:
• **G. HEINKELE ET. AL.: "Synthesis of**
[2H3]-dextromethorphan and its major urinary
metabolites [2H3]-dextrorphan and
[2H3]-dextrorphan-beta-glucoronide", JOURNAL
OF LABELLED COMPOUNDS AND
RADIOPHARMACEUTICALS, vol. 45, 2002, pages
1153-1158, XP002490642, DOI: 10.1002/jlcr.640
• **T.H. EICHHOLD ET. AL.: "Highly sensitive**
high-peformance liquid
chromatographic-tandem mass spectrometric
method for the analysis of dextromorphan in
human plasma.", JOURNAL OF
CHROMATOGRAPHY B, vol. 698, 1997, pages
147-154, XP002490644,

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- G. HEINKELE ET. AL.: "Synthesis of [2H]-labelled phase I metabolites using 1-[2H]-pyridinium hydrochloride.", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 48, 2005, pages 457-461, XP002490645, DOI: 10.1002/jlcr.941
- H. BÖLCSKEI ET. AL.: "Synthesis of deuterated dextromethorphan derivatives.", ARKIVOK, vol. 2008, no. iii, 1 March 2008 (2008-03-01), pages 182-193, XP002490643,